Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSMO study of switching from omalizumab to mepolizumab in severe eosinophilic asthma
NL-OMON43415Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in asthma and eosinophilic asthma (EA), sponsored by GSK. Primary endpoint: Mean change from baseline in ACQ-5 score at Week 32. Started Jun 2016; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON43415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43415.